companyprofile
Actions
Dallah Healthcare Co.
- Main Market
- Health Care Equipment & Svc
- Shares Type
- Common Shares
Stats Overview
-
Prev. Close 130.40
-
Open 130.40
-
High 134.10
-
Low 128.60
-
YTD% Change6.37
-
No. of Trades 2,577
-
Avg. Trade size* 67
-
Volume Traded 171,758
-
Value Traded (^) 22,748,072.30
Performance
- *Average Trade Size = Cumulative / # of Trades
- **52 Week Price Change = (Current Price - Price year ago) / Price year ago x 100
- Historical prices & volume traded data are adjusted to account for all corporate actions.
- MO: Market Order
Trade Updates
Last Trade
Best Bid
Best Offer
52 WEEK
PERFORMANCE
Compare Selected
Select a Maximum of 5 Companies
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions
AnnouncmentandCorporateAction
Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Announcements
Corporate Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Dividends
| Announced Date | Eligibility Date | Distribution Date | Distribution Way | Dividend Amount |
|---|---|---|---|---|
| 04/03/2026 | 24/03/2026 | 07/04/2026 | Account Transfer | ^0.50 |
| 03/11/2025 | 10/11/2025 | 30/11/2025 | Account Transfer | ^0.50 |
| 04/08/2025 | 17/08/2025 | 04/09/2025 | Account Transfer | ^0.50 |
| 01/06/2025 | 15/06/2025 | 29/06/2025 | Account Transfer | ^0.50 |
| 18/03/2025 | 06/04/2025 | 20/04/2025 | Account Transfer | ^0.50 |
CompanyProfilev2Financials
Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Financials
- FINANCIAL INFORMATION
- FINANCIAL STATEMENTS AND REPORTS
- Annually
- Quarterly
| Balance Sheet | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| Total Assets |
6,614,550.41
|
6,242,854.7
|
- | - |
| Total Liabilities |
2,867,530.48
|
2,770,202.71
|
- | - |
| Total Shareholders Equity (After Deducting the Minority Equity) |
3,468,556.27
|
3,203,392.97
|
- | - |
| Total Liabilities and Shareholders Equity |
6,614,550.41
|
5,973,595.67
|
- | - |
| Statement of Income | 2024-12-31 | 2023-12-31 | ||
| Total Revenue (Sales/Operating) |
3,205,733.99
|
2,942,897.7
|
- | - |
| Net Profit (Loss) before Zakat and Tax |
503,398.73
|
400,315.32
|
- | - |
| Zakat and Income Tax |
-18,222.04
|
-14,890.48
|
- | - |
| Net Profit (Loss) Attributable to Shareholders of the Issuer |
485,176.69
|
385,424.84
|
- | - |
| Total Comprehensive Income Attributable to Shareholders of the Issuer |
487,193.74
|
392,826.36
|
- | - |
| Profit (Loss) per Share |
4.83
|
3.7
|
- | - |
| Cash Flows | 2024-12-31 | 2023-12-31 | ||
| Net Cash From Operating Activities |
678,287.46
|
625,783.84
|
- | - |
| Net Cash From Investing Activities |
-357,147.12
|
-293,684.95
|
- | - |
| Net Cash From Financing Activities |
-390,123.41
|
-334,736.08
|
- | - |
| Cash and Cash Equivalents, Beginning of the Period |
235,307.73
|
237,944.91
|
- | - |
| Cash and Cash Equivalents, End of the Period |
166,324.65
|
235,307.73
|
- | - |
| All Figures in | Thousands | Thousands | ||
| All Currency In | ^ | ^ | ||
| Last Update Date | 2025-04-15 | 2024-05-12 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
| Balance Sheet | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total Assets |
8,938,371
|
8,764,055
|
8,543,730
|
6,592,521
|
| Total Liabilities |
4,429,301
|
4,349,000
|
4,199,571
|
2,889,115
|
| Total Shareholders Equity (After Deducting the Minority Equity) |
422,868
|
4,134,628
|
4,060,925
|
3,414,874
|
| Total Liabilities and Shareholders Equity |
8,938,371
|
8,764,055
|
8,543,730
|
6,592,521
|
| Statement of Income | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
| Total Revenue (Sales/Operating) |
1,061,262
|
1,062,433
|
832,753
|
847,734
|
| Net Profit (Loss) before Zakat and Tax |
149,861
|
120,961.45
|
160,796
|
141,068
|
| Zakat and Income Tax |
-5,185
|
6,696.48
|
-4,026
|
-6,378
|
| Net Profit (Loss) Attributable to Shareholders of the Issuer |
144,676
|
127,657.93
|
156,771
|
134,689
|
| Total Comprehensive Income Attributable to Shareholders of the Issuer |
144,613
|
127,699
|
156,699
|
134,689
|
| Profit (Loss) per Share |
1.4
|
1.23
|
1.59
|
1.29
|
| Cash Flows | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
| Net Cash From Operating Activities |
357,526
|
237,467
|
273,893
|
509,562
|
| Net Cash From Investing Activities |
-656,121
|
-575,014
|
-487,368
|
-263,419
|
| Net Cash From Financing Activities |
285,936
|
289,989
|
222,272
|
-273,231
|
| Cash and Cash Equivalents, Beginning of the Period |
166,325
|
166,325
|
166,325
|
235,308
|
| Cash and Cash Equivalents, End of the Period |
153,665
|
118,767
|
175,121
|
208,219
|
| All Figures in | Thousands | Thousands | Thousands | Thousands |
| All Currency In | ^ | ^ | ^ | ^ |
| Last Update Date | 2026-01-04 | 2026-01-04 | 2025-05-29 | 2025-06-16 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Peer Comparison
Note:Display data relevant only to the corresponding class of shares only
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Company Profile
Company overview
Dallah Health is one of the most trusted providers of high-quality healthcare services in the Kingdom of Saudi Arabia. The company has a distinguished track record of achievements and medical firsts since the opening of its first hospital in Riyadh in 1987. Today, Dallah Health delivers world-class medical services to over 3.7 million patients annually through a network of 13 fully-owned and affiliate hospitals, and specialized clinics, with a total capacity of more than 2,560 beds when fully operational. Dallah Health also offers comprehensive homecare services and telemedicine, all delivered by highly-experienced healthcare professionals. Since its listing on the Saudi Exchange (Tadawul) main market in 2012, Dallah Health has continued to strengthen its leadership in the Saudi healthcare sector and solidify its position as a premier destination for medical tourism, achieving some of the most prestigious international certifications and awards such as (GHA) Global Healthcare Accreditation. Its flagship hospital, Dallah Al-Nakheel, is the world''s first hospital outside the US to attain 12 surgical centers of excellence, accredited by the Surgical Review Corporation (SRC) under one roof. For more information, please visit the website: www.dallahhealth.com
Company History
Dallah Healthcare Company is a Saudi joint stock company established pursuant to Commercial Registration No. 1010128530 dated 13 Rabi Al-Thani 1415H, corresponding to 18 September 1994G. The Company has been listed on the Saudi Exchange (Tadawul) since 17 November 2012G, corresponding to 3 Muharram 1434H, under symbol (4004) within the Healthcare sector. The Company capital amounts to one billion fifteen million seven hundred forty seven thousand six hundred ninety (SAR 1,015,747,690), divided into one hundred one million five hundred seventy four thousand seven hundred sixty nine (101,574,769) shares, with a nominal value of ten (SAR 10) per share
Company Bylaws
Equity Profile
- Authorized Capital (^) 1,015,747,690
- Total Issued Shares 101,574,769
- Paid Capital (^) 1,015,747,690
- Par Value/Share 10
- Paid Up Value/Share 10
Last Update :2025-03-24
Investment limits
There are no investment limits on the company shares as per the amended Rules for Qualified Foreign Financial Institutions Investment in Listed Securities and Instructions for the Foreign Strategic Investors Ownership in Listed Companies based on company bylaw and the issued instructions by the related regulators and supervisory authorities
- Company Details
- BOARD OF DIRECTORS AND SENIOR EXECUTIVES INFORMATION
Investor Relations
Contact Name:
Investor Relations
Company Address:
Nakheel building, 1157 King Fahad Road, 2nd fl., Nakheel District, Riyadh, KSA
Contact Details:
Telephone:
0112255065-5001
Fax
: 0114550803
Email
: IR@dallahhealth.com
Company Website:
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of these disclosures, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of these disclosures, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.
- ${title}${badge}